公开(公告)号：US12129295B2

公开(公告)日：2024-10-29

申请号：US17198179

申请日：2021-03-10

申请人： BIOSCEPTRE (AUST) PTY LTD

发明人： Julian Alexander Barden ,  Neil Brewis ,  Philip Jones ,  Steven Grant

IPC分类号： C07K16/28 ,  C07K16/30

CPC分类号： C07K16/28 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

公开(公告)号：US20240352124A1

公开(公告)日：2024-10-24

申请号：US18512432

申请日：2023-11-17

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Eric Smith ,  Nicholas J. Papadopoulos

IPC分类号： C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2809 ,  C07K16/2887 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/92 ,  Y02A50/30

摘要： The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

公开(公告)号：US20240317850A1

公开(公告)日：2024-09-26

申请号：US18624860

申请日：2024-04-02

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Michael C. Milone ,  Huijuan Song ,  Enxiu Wang ,  Qilong Wu

IPC分类号： C07K16/28 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C07K14/74 ,  C07K16/30 ,  C12N5/0783

CPC分类号： C07K16/28 ,  A61K35/17 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70535 ,  C07K14/70539 ,  C07K14/7056 ,  C07K14/70596 ,  C07K16/30 ,  C12N5/0636 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N2510/00

摘要： The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

公开(公告)号：US20240279351A1

公开(公告)日：2024-08-22

申请号：US18570723

申请日：2022-06-16

申请人： REGENTS OF THE UNIVERSITY OF MINNESOTA

发明人： Bruce Walcheck ,  Martin Felices ,  Jeffrey S. Miller ,  Hemant K. Mishra ,  Kristin Snyder

IPC分类号： C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2317/76

摘要： Compounds that inhibit ADAM17 activity include a targeting domain that selectively binds to a target, an ADAM17-inhibiting domain, and a linker operably linking the targeting domain and the ADAM17-inhibiting domain. Compounds that bind to ADAM17 include one or more anti-ADAM17 binding domains that include one or more antibody fragments that bind to ADAM17. ADAM17-binding domains and/or ADAM17-inhibiting domains can be included in therapeutic compounds and/or compounds that detect ADAM17.

公开(公告)号：US20240262921A1

公开(公告)日：2024-08-08

申请号：US18643356

申请日：2024-04-23

申请人： Janssen Biotech, Inc.

发明人： Ricardo ATTAR ,  Rajkumar Ganesan ,  Francois Gaudet ,  Bradley J. Heidrich ,  Carmen Baca Jones ,  John Lee ,  Yingzhe Li ,  Sanjaya Singh ,  Sathya Venkataramani

IPC分类号： C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/2866 ,  A61K9/0019 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

摘要： The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

公开(公告)号：US20240262912A1

公开(公告)日：2024-08-08

申请号：US18528535

申请日：2023-12-04

申请人： Merus N.V.

发明人： Alexander Berthold Hendrik BAKKER ,  Cornelis Jacob Johannes George BOL ,  Pieter Fokko VAN LOO ,  Leonardo Andres SIRULNIK ,  Ernesto Isaac WASSERMAN

IPC分类号： C07K16/28 ,  A61K35/28 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/2809 ,  A61K35/28 ,  A61P35/00 ,  C07K16/2851 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/92

摘要： The disclosure relates to means and methods of treating a subject for a CLEC12A positive cancer. In some embodiments the method comprises treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration an first amount of the bispecific antibody is administered and wherein in each of the subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration. In some embodiments CLEC12A positive cancer treatment methods are provided at intervals and dosing regimens that spare hemopoietic stem cell compartment allowing for recovery of normal CLEC12A positive hemopoietic cells.

公开(公告)号：US11987640B2

公开(公告)日：2024-05-21

申请号：US17223871

申请日：2021-04-06

申请人： Fred Hutchinson Cancer Center

发明人： Colin Correnti ,  Ashok Bandaranayake ,  Christopher Mehlin ,  James M. Olson ,  Soheil Meshinchi

IPC分类号： C07K16/30 ,  C07K16/28 ,  G01N33/574 ,  A61K39/00

CPC分类号： C07K16/30 ,  C07K16/2809 ,  G01N33/57488 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/74

摘要： Mesothelin (MSLN) is expressed on pancreatic cancers, ovarian cancers and mesotheliomas. The present disclosure provides antigen-binding molecules, including anti-MSLN antibodies, and bispecific antigen-binding molecules that bind to both MSLN and a T cell antigen (e.g., CD3) and activate T cells in the presence of MSLN-expressing tumor cells. The antigen-binding molecules of this disclosure are useful for the treatment of diseases and disorders in which a MSLN-targeted immune response is desired and/or therapeutically beneficial. For example, the antigen-binding molecules of the present disclosure are useful for the treatment of various cancers, including pancreatic cancer, ovarian cancer and mesotheliomas.

公开(公告)号：US11873338B2

公开(公告)日：2024-01-16

申请号：US17294338

申请日：2019-12-20

申请人： Merus N.V.

发明人： Alexander Berthold Hendrik Bakker ,  Cornelis Jacob Johannes George Bol ,  Pieter Fokko Van Loo ,  Leonardo Andres Sirulnik ,  Ernesto Isaac Wasserman

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K35/28 ,  A61K39/00

CPC分类号： C07K16/2809 ,  A61K35/28 ,  A61P35/00 ,  C07K16/2851 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/92

摘要： The disclosure relates to means and methods of treating a subject for a CLEC12A positive cancer. In some embodiments the method comprises treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration an first amount of the bispecific antibody is administered and wherein in each of the subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration. In some embodiments CLEC12A positive cancer treatment methods are provided at intervals and dosing regimens that spare hemopoietic stem cell compartment allowing for recovery of normal CLEC12A positive hemopoietic cells.

公开(公告)号：US11845791B2

公开(公告)日：2023-12-19

申请号：US17653681

申请日：2022-03-07

申请人： MedImmune, LLC

发明人： Claire Dobson ,  Fiona Cusdin ,  Darren Schofield ,  Peter Cariuk ,  Elaine Hurt ,  Margareta Ek ,  Carina Johansson ,  Jenny Sandmark

IPC分类号： C07K16/22 ,  A61P35/00 ,  A61P21/00 ,  A61K39/00

CPC分类号： C07K16/22 ,  A61P21/00 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

摘要： The present disclosure is directed to human GDF-15-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect human GDF-15 and/or in methods of treating cancer or body weight loss, including cachexia, associated with over-expression of human GDF-15.

公开(公告)号：US20230348602A1

公开(公告)日：2023-11-02

申请号：US18186793

申请日：2023-03-20

申请人： WuXi Biologics Ireland Limited

发明人： Yong Zheng ,  Jing Li ,  Zhisheng Chen

IPC分类号： C07K16/28

CPC分类号： C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/33 ,  C07K2317/34

摘要： The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.